Table 1. Patient demographics.
| Untreated | Tysabri | Interferon | p-value | |
| Cohort I | ||||
| Number of donors | 25 (4M/21F) | 25 (9M/16F) | 25 (6M/19F) | p = 0.19 |
| Age (years) | 41.8 (22–70) | 39.1 (23–45) | 45.3 (24–65) | p = 0.15 |
| Disease duration (years) | 8.4 (0–33) | 9.7 (3–38) | 9.0 (2–26) | p = 0.81 |
| EDSS | 1.3 (0–3) | 1.8 (0–6.5) | 1.6 (0–6) | p = 0.78 |
| Treatment duration (months) | n/a | 27.5 (14–42) | 70.9 (15–147) | n.d. |
| Relapses within 24 months* | 4/14 | 3/18 | 5/16 | p = 0.68 |
| Time to relapse (months) | 7.0 (1–20) | 12.0 (3–24) | 10.4 (1–23) | n.d. |
| Cohort II | ||||
| Number of donors | 21 (1M/20F) | 19 (3M/16F) | 16 (3M/13F) | p = 0.33 |
| Age (years) | 43.4 (22–64) | 42.9 (26–56) | 46.8 (30–62) | p = 0.45 |
| Disease duration (years) | 9.8 (0–20) | 8.8 (2–22) | 9.4 (4–18) | p = 0.82 |
| EDSS | 1.1 (0–6) | 1.7 (0–6) | 1.6 (0–3) | p = 0.11 |
| Treatment duration (months) | n/a | 31.4 (5–55) | 54.4 (5–127) | n.d. |
*Number of donors with a documented relapse during 24 months of follow-up. M = male; F = female. Data is expressed as mean (range) unless otherwise specified. EDSS = Expanded Disability Status Scale. Differences between the groups were determined using ANOVA (age and disease duration), Kruskal-Wallis one-way analysis of variance (EDSS), or Fisher exact test (gender and presence of relapses; p-value shows comparison Untreated vs. Tysabri).